Evidence map›Paper›PMID 39691241›Full record

ArticleEJHaem2024

Successful treatment of low-risk myelodysplastic syndrome-related anemia in patients with chronic kidney disease with daprodustat: A report of two cases.

Hiroyoshi Kunimoto, Takayuki Sakuma, Takuma Ohashi, Mayoko Shirafuta, Hiroshi Teranaka, Hideaki Nakajima

Abstract read
In one paragraph

Article in EJHaem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hiroyoshi KunimotoDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.ORCID https://orcid.org/0009-0005-0511-2583
Takayuki SakumaDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.
Takuma OhashiDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.
Mayoko ShirafutaDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.
Hiroshi TeranakaDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.
Hideaki NakajimaDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anemia is a major clinical manifestation seen in myelodysplastic syndromes (MDS). Treatment options for anemia in low-risk MDS are limited. Especially, oral medication which is uniformly effective for anemia in low-risk MDS is required. Hypoxia-inducible factor (HIF) prolyl hydroxylase (HIF-PH) inhibitors, such as daprodustat, are oral tablets effective for renal anemia. Pharmacological restoration of HIF activity by HIF-PH inhibitors may be beneficial for MDS-related anemia as well. Yet, their efficacy and safety against low-risk MDS are unclear. Here, we report two cases of low-risk MDS complicated with chronic kidney disease whose anemia responded to daprodustat treatment.

Indexed as

anemiacase reportdaprodustatMDS

Identifiers

PMID39691241
PMCPMC11647689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.